In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet?
Hepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral therapies fuel optimism in controlling HCV infections, there are several obstacles regarding...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| التنسيق: | article |
| اللغة: | الإنجليزية |
| منشور في: |
2021
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://hdl.handle.net/20.500.12008/41395 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1868890173200138240 |
|---|---|
| author | Echeverría Chagas, Natalia |
| author2 | Comas Almada, Victoria Aldunate Caramori, Fabián Perbolianachis Duarte, Paula Moreno Karlen, María del Pilar Cristina, Juan |
| author2_role | author author author author author |
| author_browse | Aldunate Caramori, Fabián Comas Almada, Victoria Cristina, Juan Echeverría Chagas, Natalia Moreno Karlen, María del Pilar Perbolianachis Duarte, Paula |
| author_facet | Echeverría Chagas, Natalia Comas Almada, Victoria Aldunate Caramori, Fabián Perbolianachis Duarte, Paula Moreno Karlen, María del Pilar Cristina, Juan |
| author_role | author |
| collection | COLIBRI |
| dc.contributor.none.fl_str_mv | Echeverría Chagas Natalia, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares. Comas Almada Victoria, Universidad de la República (Uruguay). Facultad de Medicina. Aldunate Caramori Fabián, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares. Perbolianachis Duarte Paula, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares. Moreno Karlen María del Pilar, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares. Cristina Juan, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares. |
| dc.creator.none.fl_str_mv | Echeverría Chagas, Natalia Comas Almada, Victoria Aldunate Caramori, Fabián Perbolianachis Duarte, Paula Moreno Karlen, María del Pilar Cristina, Juan |
| dc.date.none.fl_str_mv | 2021 2023-11-21T21:50:54Z 2023-11-21T21:50:54Z |
| dc.format.none.fl_str_mv | 34 h. application/pdf |
| dc.identifier.none.fl_str_mv | Echeverría Chagas, N, Comas Almada, V, Aldunate Caramori, F. y otros. "In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet?". World Journal of Hepatology. [en línea] 2021, 13(10): 1234-1268. 34 h. DOI: 10.4254/wjh.v13.i10.1234. 1948-5182 https://hdl.handle.net/20.500.12008/41395 10.4254/wjh.v13.i10.1234 |
| dc.language.none.fl_str_mv | en eng |
| dc.publisher.none.fl_str_mv | Baishideng |
| dc.relation.none.fl_str_mv | World Journal of Hepatology, 2021, 13(10): 1234-1268. |
| dc.rights.none.fl_str_mv | info:eu-repo/semantics/openAccess Licencia Creative Commons Atribución (CC - By 4.0) |
| dc.source.none.fl_str_mv | reponame:COLIBRI instname:Universidad de la República instacron:Universidad de la República |
| dc.subject.none.fl_str_mv | Hepatitis C virus Vaccine candidates Nucleic acid-based vaccines Recombinant vector-based vaccines Challenges COVID-19 |
| dc.title.none.fl_str_mv | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? |
| dc.type.none.fl_str_mv | Artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| description | Hepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral therapies fuel optimism in controlling HCV infections, there are several obstacles regarding treatment accessibility and reinfection continues to remain a possibility. Indeed, the majority of new HCV infections in developed countries occur in people who inject drugs and are more plausible to get reinfected. To achieve global epidemic control of this virus the development of an effective prophylactic or therapeutic vaccine becomes a must. The coronavirus disease 19 (COVID-19) pandemic led to auspicious vaccine development against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, which has renewed interest on fighting HCV epidemic with vaccination. The aim of this review is to highlight the current situation of HCV vaccine candidates designed to prevent and/or to reduce HCV infectious cases and their complications. We will emphasize on some of the crossroads encountered during vaccine development against this insidious virus, together with some key aspects of HCV immunology which have, so far, hampered the progress in this area. The main focus will be on nucleic acid-based as well as recombinant viral vector-based vaccine candidates as the most novel vaccine approaches, some of which have been recently and successfully employed for SARS-CoV-2 vaccines. Finally, some ideas will be presented on which methods to explore for the design of live-attenuated vaccines against HCV. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | anni_b6722c9976d5bfbee7be55c187d18cf8 |
| identifier_str_mv | Echeverría Chagas, N, Comas Almada, V, Aldunate Caramori, F. y otros. "In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet?". World Journal of Hepatology. [en línea] 2021, 13(10): 1234-1268. 34 h. DOI: 10.4254/wjh.v13.i10.1234. 1948-5182 10.4254/wjh.v13.i10.1234 |
| instacron_str | Universidad de la República |
| institution | Universidad de la República |
| instname_str | Universidad de la República |
| language | eng |
| language_invalid_str_mv | en |
| network_acronym_str | anni |
| network_name_str | oai-lr-anni |
| oai_identifier_str | oai:colibri.udelar.edu.uy:20.500.12008/41395 |
| publishDate | 2021 |
| publishDateSort | 2021 |
| publisher.none.fl_str_mv | Baishideng |
| reponame_str | COLIBRI |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | Licencia Creative Commons Atribución (CC - By 4.0) |
| spelling | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet?Echeverría Chagas, NataliaComas Almada, VictoriaAldunate Caramori, FabiánPerbolianachis Duarte, PaulaMoreno Karlen, María del PilarCristina, JuanHepatitis C virusVaccine candidatesNucleic acid-based vaccinesRecombinant vector-based vaccinesChallengesCOVID-19Hepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral therapies fuel optimism in controlling HCV infections, there are several obstacles regarding treatment accessibility and reinfection continues to remain a possibility. Indeed, the majority of new HCV infections in developed countries occur in people who inject drugs and are more plausible to get reinfected. To achieve global epidemic control of this virus the development of an effective prophylactic or therapeutic vaccine becomes a must. The coronavirus disease 19 (COVID-19) pandemic led to auspicious vaccine development against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, which has renewed interest on fighting HCV epidemic with vaccination. The aim of this review is to highlight the current situation of HCV vaccine candidates designed to prevent and/or to reduce HCV infectious cases and their complications. We will emphasize on some of the crossroads encountered during vaccine development against this insidious virus, together with some key aspects of HCV immunology which have, so far, hampered the progress in this area. The main focus will be on nucleic acid-based as well as recombinant viral vector-based vaccine candidates as the most novel vaccine approaches, some of which have been recently and successfully employed for SARS-CoV-2 vaccines. Finally, some ideas will be presented on which methods to explore for the design of live-attenuated vaccines against HCV.BaishidengEcheverría Chagas Natalia, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares.Comas Almada Victoria, Universidad de la República (Uruguay). Facultad de Medicina.Aldunate Caramori Fabián, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares.Perbolianachis Duarte Paula, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares.Moreno Karlen María del Pilar, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares.Cristina Juan, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares.2023-11-21T21:50:54Z2023-11-21T21:50:54Z2021Artículoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion34 h.application/pdfEcheverría Chagas, N, Comas Almada, V, Aldunate Caramori, F. y otros. "In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet?". World Journal of Hepatology. [en línea] 2021, 13(10): 1234-1268. 34 h. DOI: 10.4254/wjh.v13.i10.1234.1948-5182https://hdl.handle.net/20.500.12008/4139510.4254/wjh.v13.i10.1234reponame:COLIBRIinstname:Universidad de la Repúblicainstacron:Universidad de la RepúblicaenengWorld Journal of Hepatology, 2021, 13(10): 1234-1268.Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)info:eu-repo/semantics/openAccessLicencia Creative Commons Atribución (CC - By 4.0)oai:colibri.udelar.edu.uy:20.500.12008/413952026-04-14T10:10:22Z |
| spellingShingle | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? Echeverría Chagas, Natalia Hepatitis C virus Vaccine candidates Nucleic acid-based vaccines Recombinant vector-based vaccines Challenges COVID-19 |
| status_str | publishedVersion |
| title | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? |
| title_full | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? |
| title_fullStr | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? |
| title_full_unstemmed | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? |
| title_short | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? |
| title_sort | In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? |
| topic | Hepatitis C virus Vaccine candidates Nucleic acid-based vaccines Recombinant vector-based vaccines Challenges COVID-19 |
| url | https://hdl.handle.net/20.500.12008/41395 |